News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Preclinical Data On Predix Pharmaceuticals' 5-HT6 Antagonist For Obesity And Cognitive Impairment To Be Presented At Serotonin Club Meeting In Japan


6/29/2006 10:48:36 AM

LEXINGTON, Mass.--(BUSINESS WIRE)--June 29, 2006--Predix Pharmaceuticals, which recently announced a definitive agreement to merge with EPIX Pharmaceuticals (NASDAQ:EPIX - News), announced today that preclinical data from studies in obesity and cognitive impairment with PRX-07034, a highly selective, proprietary 5-HT6 receptor antagonist, will be presented at the Serotonin Club Meeting 2006. Predix recently entered PRX-07034 into Phase I clinical development as a small-molecule drug candidate with the potential to treat obesity and also cognitive impairment (associated with Alzheimer's disease or schizophrenia).

Read at press release

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES